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DynamicsPhospholamban (PLB) is an integral membrane protein regulating Ca2+ transport through inhibitory
interaction with sarco(endo)plasmic reticulum calcium ATPase (SERCA). The Asn27 to Ala (N27A) mutation
of PLB has been shown to function as a superinhibitor of the afﬁnity of SERCA for Ca2+ and of cardiac
contractility in vivo. The effects of this N27A mutation on the side-chain and backbone dynamics of PLB were
investigated with 2H and 15N solid-state NMR spectroscopy in phospholipid multilamellar vesicles (MLVs).
2H and 15N NMR spectra indicate that the N27A mutation does not signiﬁcantly change the side-chain or
backbone dynamics of the transmembrane and cytoplasmic domains when compared to wild-type PLB.
However, dynamic changes are observed for the hinge region, in which greater mobility is observed for the
CD3-labeled Ala24 N27A-PLB. The increased dynamics in the hinge region of PLB upon N27A mutation may
allow the cytoplasmic helix to more easily interact with the Ca2+-ATPase; thus, showing increased inhibition
of Ca2+-ATPase.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Phospholamban (PLB) is a 52-amino acid integral membrane
protein that regulates the activity of sarco(endo)plasmic reticulum
calcium ATPase (SERCA), which controls the uptake of Ca2+ from the
sarcoplasmic reticulum (SR). This mechanism controls the contrac-
tion–relaxation cycle of the heart [1,2]. The relief of SERCA inhibition
is achieved by phosphorylation of PLB at Ser16 by protein kinase A
and/or Thr17 by Ca2+/calmodulin-dependent protein kinases [3]. In
its non-phosphorylated form, PLB inhibits SERCA activity, whereas
phosphorylation of PLB relieves the inhibition. PLB also oligomerizes
into pentamers through a leucine–isoleucine zipper interaction in the
transmembrane domain [4]. Several studies revealed that the PLB
pentamer depolymerizes into active monomers that bind and inhibit
SERCA and that an L37A mutation destabilizes the PLB oligomers
[4–6]. Recent studies have also indicated that the pentameric form of
PLB can co-crystallize with SERCA [7].
Solution NMR, solid-state NMR, and EPR spectroscopic techniques
have been extensively used to investigate the structure and dynamics
of membrane proteins in general and PLB in particular in various
membrane environments [8–18]. In dodecylphosphocholine (DPC)
micelles, monomeric AFA-PLB (where all three native Cys residues 36,oss-polarization magic-angle-
oyl-sn-glycero-3-phosphocho-
eticulum; SERCA, sarco(endo)
+1 513 529 5715.
an).
ll rights reserved.41 and 46 of PLB are replaced with Ala) takes on an “L-shape” with a
cytoplasmic a-helical domain Ia (residues 2–16) connected to another
transmembrane a-helical domain (residues 22–50) through a loop
(residues17–21) [12] (Fig. 1). Based on nuclear spin relaxation and
solvent accessibility experiments, the segment 23–52 is further
subdivided into two dynamic domains: domain Ib (residues 23–30)
and domain II (residues 31–52) [14]. One of the noticeable diversities
in the reported structures of PLB, however, is the structure and
dynamics of the cytoplasmic domain. In the “pinwheel” structure of
the wild-type pentameric form of PLB, the cytoplasmic domains
interact with the membrane surface, and a dynamic equilibrium
between the two conformational states (“L-shaped” form or “T-state”,
and extended form or “R state”) was proposed to account for the
regulatory mechanism of PLB [12–14]. In the “bellﬂower” structure of
PLB pentamers in DPC micelles, the cytoplasmic a-helical domains of
PLB are pointing away from the membrane surface [15]. Solid-state
NMR studies on AFA-PLB incorporated into 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) lipid bilayers indicate that the
cytoplasmic domain exhibits a high degree of structural disorder [16].
Additional solid-state NMR studies of PLB in the presence of Ca2+-
ATPase, did not detect the presence of a populated dynamic state of
PLB after formation of the PLB/SERCA complex [17].
Structural studies provide a clearer and more complete picture on
the working mechanism of PLB, but there are still several unresolved
issues, especially the conformation and dynamics of the cytoplasmic
domain. It should also be noted that the static three-dimensional PLB
structure itself does not immediately make the working mechanism
clear. Protein dynamics have been shown to play an integral role in
the function of membrane protein systems [19–21].
Fig. 1. Amino acid sequence of wild-type phospholamban. The 2H-labeling sites are
Ala15, Ala24, and Leu42, and the 15N-labeling sites are Ala11 and Leu42. The four
dynamic domains are: Ia (residues 1–16), loop (residues 17–22), Ib (residues 23–30)
and II (residues 31–52), following the convention in ref. [12].
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transmembrane domain and the cytoplasmic domain. The hinge loop
of PLB that connects the two a-helixes has been suggested to regulate
a long-range coupling between the cytoplasmic domain and the
transmembrane domain and has unique structural and functional
implications [22–24]. Speciﬁcally, the Asn27 to Ala mutant (N27A-
PLB)maintains a normal pentamer tomonomer ratio, has been shown
to be a superinhibitor of SERCA Ca2+ afﬁnity and of cardiac
contractility in vivo, and to be involved in heart failure [24]. This
mutation in the hinge region of PLB was reported to be involved in the
structural and functional roles in transmitting PLB's regulatory effects
on SERCA [23].
Previously, we have investigated the wild-type PLB as well as its
phosphorylated form in lipid membranes with different solid-state
NMR spectroscopic techniques [25–30]. In the present study, the
effects of the N27A mutation on the side-chain and backbone
dynamics of PLB were investigated using solid-state 2H and 15N
NMR spectroscopy of site-speciﬁcally b-methyl (CD3) labeled Ala and
δ-methyl labeled Leu, or 15N-amide labeled Ala and Leu, located in the
three domains of PLB, respectively.
2. Materials and methods
2.1. Materials
All synthetic phospholipids were purchased from Avanti Polar
Lipids (Alabaster, AL). The phospholipids were dissolved in chloro-
form and stored at−20 °C before use. 2,2,2-Triﬂuoroethanol (TFE), N-
[2-hydroxyethyl]piperazine-N′-2-ethane sulfonic acid (HEPES) and
acrylamide were obtained from Sigma-Aldrich (St. Louis, MO). Fmoc
amino acids and other chemicals for peptide synthesis were
purchased from Novabiochem (San Diego, CA). 15N- and 2H- L-Ala
N-Fmoc derivative, 15N- and 2H- L-Leu N-Fmoc derivative, 15NH4Cl,
and deuterium-depleted water were purchased from Isotec™/Sigma-
Aldrich (Miamisburg, OH). Precise™ protein pre-cast gels and protein
molecular weight markers for sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) were purchased from Thermo
Scientiﬁc (Rockford, IL) and Invitrogen (Carlsbad, CA), respectively.
2.2. Peptide synthesis, puriﬁcation and characterization
The peptides were synthesized with an ABI 433A peptide
synthesizer (Applied Biosystems, Foster City, CA) using the Fast-
ﬂuorenylmethoxycarbonyl strategy as descried previously [29]. The
peptides were puriﬁedwith an ÄKTA™ puriﬁer HPLC chromatography
system (GE Healthcare (Pharmacia) Uppsala, Sweden) equipped with
a reverse-phase polymer column. The peptides were lyophilized and
then characterized with an Ultraﬂex™ matrix-assisted laser desorp-
tion ionization time-of-ﬂight/time-of-ﬂight (MALDI-TOF/TOF) mass
spectrometer (Bruker Daltonics Inc. Billerica, MA).
SDS-PAGE of the synthetic wild-type PLB and N27A-PLB mutant
was conducted according to Wegener and Jones [31] using a 4 to 15%
acrylamide gradient in the resolving gel. After electrophoresis, the gel
was stained for 30 min with Coomassie Blue followed by overnight
destaining.The circular dichroism (CD) spectra of PLB and N27A-PLB were
collected in different media including TFE/H2O (80:20) solvent and
1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC) micelles with
a J-810 circular dichroism spectropolarimeter (JASCO Inc. Easton,
MD). The measurements were conducted at 25 °C in a water-jacketed
1 mm cylindrical quartz cuvette (Hellma Int. Inc. Plainview, NY) over
the wavelength range 180–300 nm. Each spectrumwas the average of
eight scans and was corrected for spurious signals generated by the
medium. The peptide concentrations were determined by absorbance
at 280 nm on a NanoDrop® UV/visible spectrophotometer (Nano-
Drop, Wilmington, DE).
2.3. Sample preparation
For 2H- and 15N- solid-state NMR experiments, site-speciﬁc 2H- or
15N-labeled WT-PLB or N27A-PLB sample were prepared in 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) as de-
scribed previously [29]. Approximately 11 mg of the isotope-labeled
peptide was ﬁrst dissolved in a minimal amount of TFE prior to
cosolubilizing with 35 mg of the POPC lipids (at a peptide
concentration of 4 mol% with respect to lipids). The chloroform
and TFE solvents were removed slowly under a steady stream of N2
gas and the samples were dried overnight in a vacuum desiccator.
The resulting mixtures were hydrated with 95 mL HEPES buffer
(30 mM HEPES, and 20 mM NaCl, pH 7.0). The hydrated samples
underwent through 5–10 freeze–thaw cycles using liquid nitrogen to
increase the homogeneity of the vesicles. The pellet (60–80 mg) was
transferred to a 4 mm MAS rotor for 2H and 15N NMR spectroscopic
studies.
2.4. Solid-state NMR spectroscopy
All NMR experiments were performed on a 500 MHz Bruker
Avance wide-bore NMR spectrometer (Bruker BioSpin, Rheinstetten,
Germany) using a 4 mm triple resonance CP-MAS probe (Bruker
BioSpin).
2H NMR spectra were acquired at a 2H frequency of 76.773 MHz.
A quadrupolar echo pulse sequence (90°–τ1–90°–τ2–acquire) [32]
was used, with a recycle delay of 300 ms, echo delay τ1 of 40 μs, τ2 of
35 μs, and 2H 90° of 3.0 μs. The spectral width was set to 100 kHz.
20 K scans were averaged and the free induction delays (FIDs) were
processed with a linebroadening of 200 Hz with the Bruker Topspin
2.0 software.
15N NMR spectra were acquired at a 15N frequency of 50.680 MHz
using a RAMP cross-polarization pulse sequence with 1H decoupling.
A 4.8 ms 1H 90° pulse, 1.5 ms contact time, 500 ppm sweepwidth, and
a 4 s recycle delay were used. 120 K scans were averaged for the static
15N CP NMR experiments at −25 °C and 25 °C respectively. The FIDs
were processed with a linebroadening of 300 Hz. 15N NMR spectra
were simulated with the DMFIT software program [33].
3. Results and discussion
3.1. SDS-PAGE gel and circular dichroism spectra of wild-type PLB and
N27A-PLB
The oligomerization states of the synthetic N27A-PLB mutant as
well as the wild-type PLB were investigated with SDS-polyacryl-
amide gel electrophoresis. As shown in Fig. 2 in the left lane, the
band above 22 kDa was suggested to be the pentameric form of
wild-type PLB [34]. The SDS-PAGE gel shows that both the wild-
type PLB and the N27A-PLB mutant are predominantly in the
pentameric states and their migration patterns are very similar to
each other. The N27A mutation does not signiﬁcantly change the
oligomerization state of PLB, which is consistent with the previous
reports where the PLB N27A mutant exhibits primarily pentameric
Fig. 2. SDS-PAGE of the synthetic wild-type PLB and N27A-PLB mutant. PLB was loaded
on a 4–15% polyacrylamide gradient gel. After electrophoresis, the gel was stained with
Coomassie blue followed by overnight destaining.
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SERCA2a, the monomer percent was calculated to be 10.1% for
N27A-PLB, while wild-type PLB exists in 10.9% monomer form [22].
The comparable pentamer:monomer ratios of wild-type PLB and
N27A-PLB avoid the potential effects of different oligomerization
states on the structural and dynamical properties discussed in this
manuscript.
Fig. 3 shows the circular dichroism spectra of both wild-type PLB
and the N27A-PLB mutant. The spectra indicate that the proteins are
largely a-helical when reconstituted into DHPC micelles as well as in
TFE/H2O solvent, as seen from the characteristic positive signal at
190 nm and two negative ellipticity humps at 207 and 222 nm, which
are in well agreement with the previous results [35,36]. CD
measurements also provide an estimate of the percentage of a-helix
formation. The N27A mutation of PLB decreases the a-helical
secondary structure percentage slightly, as indicated by the decreased
ellipticity of N27A-PLB when compared with WT-PLB after normal-
izing the ellipticity against the peptide concentration. The reduced a-Fig. 3. Circular dichroism spectra of wt-PLB (in red) and the N27A-PLB mutant (in blue)
recorded in TFE/H2O (80:20) (dotted lines) or in DHPC micelles (solid lines) at 25 °C.
The spectra, presenting in terms of mean residue ellipticity in [deg cm2 domle−1], were
normalized against the peptide concentration after subtracting the contributions from
the solvent and lipid vesicles.helical secondary structure percentage is consistent with a previous
report, which showed that the presence of a N27A mutation
decreased the helical content of PLB [23].
3.2. 2H-NMR and side-chain dynamics
Fig. 4 shows the solid-state 2H NMR spectra of site-speciﬁc CD3-
labeled N27A-PLB at residues Leu42, Ala24 and Ala15 incorporated
into POPC MLVs, along with the corresponding 2H NMR data of wild-
type PLB [29]. The three residues are located in the transmembrane
domain, linker region, and cytoplasmic domain respectively. The
spectra were collected over a temperature range from −25 °C to
50 °C.
The 2H quadrupolar splitting ΔνQ is deﬁned in Eq. (1) and can be
used to describe the motional dynamics of the site-speciﬁc CD3 group
labeled peptide reconstituted into randomly dispersed MLVs:
ΔνQ =
3
8
e2Q
q
h
Smol 3 cos
2 θi − 1
 
ð1Þ
where e2Qq/h is the nuclear quadrupolar coupling constant (165–
170 kHz for a C–D bond) [37,38], Smol is the molecular order
parameter reﬂecting orientational ﬂuctuations of the C–D bond
relative to the bilayer normal, and θi is the average orientation of
each C–D bond relative to the bilayer normal.
At −25 °C, the 2H NMR spectra of N27A-PLB with CD3-labeled
at positions Leu42, Ala24 and Ala11 reveal a broad component that
is typical of 2H powder pattern spectra having a symmetric Pake
doublet. This broad component is from a population of species
undergoing slow rotational motions [39,40]. At this temperature,
the 2H NMR spectra of all three site-speciﬁcally labeled residues of
N27A-PLB show similar lineshapes when compared with that of
corresponding wild-type PLB residues [29]. However, the 2H NMR
spectrum of the CD3-labeled Ala24 N27A-PLB (Fig. 4B) shows a
quadrupolar splitting of about 36.7 kHz, which is slightly reduced
from the ΔνQ value (∼40 kHz) of the corresponding wild-type PLB.
The decreased splitting suggests that the cytoplasmic domain may
be more mobile after the N27A mutation or possibly that the C–D
bond could be at a slightly different orientation relative to the
bilayer.
At 0 °C, slightly above the POPC's gel-to-lipid-crystalline phase
transition temperature (−3 °C), the 2H NMR lineshapes show
dramatic differences when comparing the different CD3-labeling
amino acid residue positions. As shown in Fig. 4A, the 2H NMR
lineshapes of 2H-Leu42 N27A-PLB reveal a broad component as well
as an isotropic component, representing slow motion and rapid
motion respectively. This result is very similar to that of wild-type PLB
(Fig. 4D).
However, at 0 °C (as shown in Fig. 4B), the 2H NMR spectrum of 2H-
Ala24 N27A-PLB reveals an isotropic peak, suggesting that rapid
isotropic motion is dominant at this Ala24 position after N27A
mutation when compared to the reduced broad component observed
in wild-type PLB with CD3-labeling at the same position (Fig. 4E). This
dramatic change in 2H NMR lineshapes indicates that the N27A
mutation of PLB leads to more mobile residues at position 24 around
the linker region [40].
In Fig. 4C, the 2H NMR spectrum of 2H-Ala15- N27A-PLB also shows
a comparable isotropic peak, which is similar with that observed in
wild-type PLB with a 2H-label at the same position (Fig. 4F). Both
N27A-PLB and wild-type PLB show rapid motion in the cytoplasmic
domain as represented by 2H-NMR of 2H-Ala15 PLB.
When the sample temperature was increased to 25 °C and further
to 50 °C, slow motion was still observed in the transmembrane
domain as revealed by the 2H NMR of 2H-Leu42 N27A-PLB in Fig. 4A.
But only rapid isotropic motion can be observed in the linker region
Fig. 4. 2H powder NMR spectra of the N27A-PLB mutant with site-speciﬁc CD3-labels at Leu42 (A) and Ala24 (B), and Ala15 (C) recorded in POPCMLVs at different temperatures. The
corresponding 2H NMR spectra of wild-type PLB collected in the same membrane are shown in (D–F) (ref. [29]) for direct comparison.
Fig. 5. 15N powder NMR spectra of N27A-PLB with site-speciﬁc 15N-labels at Ala11 (A, C) and Leu42 (B, D) reconstituted into POPC MLVs at −25 °C and 25 °C, respectively. The
correspondingWT 15N NMR powder spectra are shown in (E) and (F). The smooth simulated spectrum (solid line) in (C) was generated by summation of two CSA components (two
dotted lines). The smooth simulated spectrum in (D) was generated using one CSA component.
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dynamic properties of the Ib domain after N27A mutation are clearly
visible when comparing Fig. 4B and E.
3.3. 15N-NMR and backbone dynamics
The effect of N27Amutation on the backbone dynamics of PLB was
further investigated with 15N NMR of site-speciﬁc 15N-labels at Ala11
and Leu42 PLB incorporated into POPCMLVs (Fig. 5A–D), representing
the cytoplasmic domain and the transmembrane domain of PLB
respectively. The 15N NMR spectra were collected at both −25 and
25 °C. As expected, at both−25 °C and 25 °C, the 15N NMR spectra of
15N-Leu42 N27A-PLB (Fig. 5B and D) reveal powder pattern spectra
that are very similar with that of WT-PLB (Fig. 5F), and the simulation
of 15N NMR spectrum at 25 °C gave very similar 15N chemical shift
tensors (σ11 of 56, σ22 of 78 and σ33 of 228 ppm) and chemical shift
anisotropy width (CSA width of 172 ppm) when compared with that
of the corresponding 15N-labeled wild-type PLB [29], suggesting that
N27A mutation does not induce signiﬁcant changes in the transmem-
brane backbone dynamics of PLB. The 15N CSA results are similar to
other patterns observed in the literature [40,41]. The 15N NMR
spectrum of PLB N27A labeled at Leu42 showed only one broad
powder pattern component at 25 °C, indicating that these amide sites
are immobile on the 15N NMR time scale in POPC bilayers at room
temperature.
However, as shown in Fig. 5C at 25 °C, the 15N NMR spectrum of
N27A-PLB with 15N-labeling at Ala11 yields an isotropic component
as well as a powder pattern component. This indicates that the
cytoplasmic domain of N27A-PLB has two main different confor-
mational populations: one that is immobile and a second compo-
nent that is dynamically averaged on the 15N NMR time scale. This
isotropic component observed for the cytoplasmic domain of Ala11
disappears at −25 °C as shown in Fig. 5A, conﬁrming that the
isotropic component observed at 25 °C results from peptide
backbone motion.
4. Discussion
The PLB N27A mutant has been shown to function as a super-
inhibitor of SERCA Ca2+ afﬁnity and cardiac contractility in vivo [24],
and the increased inhibition of Ca2+ sequestration may be a causative
factor ﬁnally leading to heart failure [23]. The subcellular mechanisms
of the enhanced inhibitory function of pentameric N27A-PLB mutant
are not clear at this time.
As shown in Fig. 2 as well as other previous studies [22,24], the
N27A mutation does not change the oligomerization state of wild-
type PLB with the pentamer still being the dominant form. The
pentameric N27A-PLBmutant provides an interesting system to study
the structural and dynamic properties upon comparison with the
pentameric WT form of PLB.
Analysis of the CD spectra in Fig. 3 indicates that the a-helical
content of PLB decreases slightly upon N27A mutation. This data
agrees with solution NMR studies which revealed an alternation in the
a-helical conﬁguration between residues Gln22 to Phe35 for the
N27A-PLB mutant [23].
It is generally accepted that wild-type PLB consists of an a-helical
transmembrane domain connected to a mobile a-helical cytoplasmic
domain via a less structurally ordered linker region. The exact starting
and ending positions of these three regions proposed in the literature
are not consistent and may be dependent on the exact reconstituted
environment of membrane-bound PLB [9–11,13,15–16]. A very recent
solid-state NMR study indicated that in the presence of SERCA, AFA-
PLB has a short N-terminal (Val4–Arg13) and a long C-terminal
(Gln29–Val49) helix intersected by a linker of reduced structural
order from Arg14 to Gln22, and the C-terminal helix comprised of
residues Ala24–Gln26 [17].PLB regulates intracellular SR Ca2+ homeostasis through inhibitory
interaction with SR Ca2+-ATPase. The 27 position of PLB is believed to
play a crucial role in interacting with Ca2+ ATPase [22–24]. The hinge
region in PLB may interact directly with the SR Ca2+ ATPase [42].
Interaction of domain Ib with Ca2+-ATPase is supported by the
enhanced inhibitory capacity of the N27A mutant. In particular, based
on chemical cross-linking studies, it has been suggested that an
interaction of the PLB transmembrane helix at Asn27 with the
cytosolic extension of the transmembrane helix 4 (M4) of SERCA at
Leu321 leads to a potential unwinding of the helix [43].
The amino acid sequence of PLB is highly conserved, and although
all species contain asparagine (Asn) at residue 27, human PLB is
unique in containing a lysine (Lys). Both asparagine and lysine have a
carboxamide group and an ɛ-amino group respectively which often
form hydrogen bond interactions with the peptide backbone.
Asparagine residues are generally found near the beginning and the
end of a-helices. Its role can be thought as “capping” the hydrogen
bonding interactions which would otherwise be satisﬁed by the
polypeptide backbone. It has been suggested that this unique amino
acid sequence at the 27 position may be critical in maintaining a high
cardiac reserve [44].
As expected, the N27A mutation does not induce dramatic
dynamic changes in the transmembrane a-helix as monitored with
2H or 15N site-speciﬁc labels at position Leu42. However, the N27A
mutation increased the side-chain dynamics at Ala24 as revealed from
2H NMR. Because the CD3 group in Ala is directly connected to the a-
carbon, the C–D bonds can undergo isotropic reorientation only if the
backbone of the residues undergoes isotropic reorientation owing to
the constraints imposed by the side chains [40]. Thus, the dynamic
motions observed in the case of the CD3 group of Ala reﬂect the
dynamics of the backbone. The results suggest increased backbone
dynamics at the 24 position upon N27Amutation. The superinhibitory
effects resulting from the N27Amutation may involve conformational
changes that enhance the association between PLB and SERCA. An
enhanced association between PLB and SERCA would be consistent
with the inability of phosphorylation, to provide full relief of the
superinhibitory effect of the N27A-PLB mutant [24]. This may
illustrate again that the structural dynamics of PLB can be “tuned”,
either by mutation or by phosphorylation to control its inhibition
function on SERCA [45].
PLB, as an inhibitor, decreases the afﬁnity of SERCA for Ca2+. N27A-
PLB, functioning as a superinhibitor, decreases the afﬁnity of SERCA
for Ca2+ even more when compared to the wild-type PLB. The
increased mobility of Ala24 in the linker region upon N27A mutation
may introduce more conformational ﬂexibility of the hinge region
which may be beneﬁcial for the adaption of the cytoplasmic and
transmembrane SERCA binding sites. The easier adaption may
enhance the association between N27A-PLB and SERCA, thus,
resulting in the super inhibitory effect of N27A-PLB.
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